Attached files
| file | filename |
|---|---|
| EX-32.1 - EXHIBIT 32.1 - Akoya Biosciences, Inc. | tm2115525d1_ex32-1.htm |
| EX-31.2 - EXHIBIT 31.2 - Akoya Biosciences, Inc. | tm2115525d1_ex31-2.htm |
| EX-31.1 - EXHIBIT 31.1 - Akoya Biosciences, Inc. | tm2115525d1_ex31-1.htm |
| 10-Q - FORM 10-Q - Akoya Biosciences, Inc. | tm2115525d1_10q.htm |
Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Akoya Biosciences, Inc. (the “Company”) on Form 10-Q for the quarterly period ended March 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:
| 1. | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and |
| 2. | The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company. |
| Date: May 19, 2021 | By: | /s/ Joseph Driscoll |
| Joseph Driscoll | ||
| Chief Financial Officer | ||
| (Principal Financial Officer and | ||
| Principal Accounting Officer) |